TFF Pharmaceuticals, Uniphar Durbin Ireland Open Expanded Access Program for Voriconazole Inhalation Powder For Pulmonary Aspergillosis And Other Voriconazole Responsive Fungal Pulmonary Infections
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals and Uniphar Durbin Ireland have opened an expanded access program for Voriconazole Inhalation Powder, a treatment for pulmonary aspergillosis and other voriconazole responsive fungal pulmonary infections.
July 31, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TFF Pharmaceuticals' expanded access program for Voriconazole Inhalation Powder could potentially increase the company's market share and revenues.
The expanded access program for Voriconazole Inhalation Powder could potentially increase TFF Pharmaceuticals' market share and revenues by making the treatment more widely available to patients. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100